Cognito Therapeutics, Inc.

Seasoned investors are increasingly distinguishing between flashy AI technologies and those that meaningfully accelerate therapeutic development or reduce costs. While nearly $10bn in potential allia

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

When Otsuka Pharmaceutical Co. Ltd. won US Food and Drug Administration approval for the first digital pill, Abilify MyCite (aripiprazole tablets with sensor), in 2017, it was viewed as an important

Those in support of the US FDA’s approval this year of Biogen, Inc. ’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease (AD) like to point out the parallels to the regulator’s approach i